- Connolly, Anne;
- Malkus, Elizabeth;
- Mendell, Jerry;
- Flanigan, Kevin;
- Miller, J;
- Schierbecker, Jeanine;
- Siener, Catherine;
- Golumbek, Paul;
- Zaidman, Craig;
- Johnson, Linda;
- Nicorici, Alina;
- Karachunski, Peter;
- Day, John;
- Kelecic, Jason;
- Lowes, Linda;
- Alfano, Lindsay;
- Darras, Basil;
- Kang, Peter;
- Quigley, Janet;
- Pasternak, Amy;
- Florence, Julaine;
- McDonald, Craig
INTRODUCTION: Therapeutic trials in Duchenne muscular dystrophy (DMD) often exclude non-ambulatory individuals. Here we establish optimal and reliable assessments in a multicenter trial. METHODS: Non-ambulatory boys/men with DMD (N = 91; 16.7 ± 4.5 years of age) were assessed by trained clinical evaluators. Feasibility (percentage completing task) and reliability [intraclass correlation coefficients (ICCs) between morning and afternoon tests] were measured. RESULTS: Forced vital capacity (FVC), assessed in all subjects, showed a mean of 47.8 ± 22% predicted (ICC 0.98). Brooke Upper Extremity Functional Rating (Brooke) and Egen Klassifikation (EK) scales in 100% of subjects showed ICCs ranging from 0.93 to 0.99. Manual muscle testing, range of motion, 9-hole peg test, and Jebsen-Taylor Hand Function Test (JHFT) demonstrated varied feasibility (99% to 70%), with ICCs ranging from 0.99 to 0.64. We found beneficial effects of different forms of corticosteroids for the Brooke scale, percent predicted FVC, and hand and finger strength. CONCLUSIONS: Reliable assessment of non-ambulatory boys/men with DMD is possible. Clinical trials will have to consider corticosteroid use.